Study identifier:1839IL/0057
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II trial to assess the efficacy of IRESSA™ (gefitinib) 500 mg/day in patients with breast cancer who have failed tamoxifen or have an oestrogen receptor negative tumour and would be considered for systemic therapy
Breast Cancer
Phase 2
No
gefitinib (IRESSA™, ZD1839)
Female
54
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|